免疫治療薬の世界市場:モノクローナル抗体、免疫チェックポイント阻害薬、ワクチン、非特異的免疫療法...市場調査レポートについてご紹介

【英文タイトル】Global Immunotherapy Drugs 2016-2020

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings
• Assumptions

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Overview: Immunotherapy
• Types of immunotherapy
• Key events
• Reimbursement policies
• Orphan drug designation and regulatory approvals

PART 06: Pipeline portfolio
• Anticipated number of immuno-oncology pipeline assets with single and multiple indications by 2020

PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 08: Market segmentation by type of immunotherapy
• mAbs
• Immune checkpoint inhibitors
• Vaccines
• Non-specific immunotherapies

PART 09: Market segmentation by therapy area

PART 10: Geographical segmentation
• Global immunotherapy drugs market by geographical segmentation 2015-2020
• Immunotherapy drugs market in Americas
• Immunotherapy drugs market in EMEA
• Immunotherapy drugs market in APAC

PART 11: Market drivers
• Growing prevalence of cancer and autoimmune diseases
• Rise in older population
• Increase in demand for mAbs
• Patient assistance programs
• Promising pipeline

PART 12: Impact of drivers

PART 13: Market challenges
• Patent expiries of top-selling drugs
• High costs of biologicals
• Poor diagnosis and screening
• Adverse effects
• Stringent regulations

PART 14: Impact of drivers and challenges

PART 15: Market trends
• Increase in awareness programs
• Emergence of targeted and combination therapies
• Emergence of biosimilars
• Strategic alliances
• Expected entry of novel vaccines

PART 16: Vendor landscape
• Competitive scenario
• Market share analysis 2015
• F. Hoffmann-La Roche
• AbbVie
• Johnson & Johnson
• Merck
• Amgen
• BMS
• Other prominent vendors

PART 17: Appendix
• List of abbreviations

PART 18: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Types of immunotherapy
Exhibit 03: Key events in discovery and approvals of immunotherapy drugs
Exhibit 04: Immunotherapy drugs approved by US FDA in 2015
Exhibit 05: US FDA orphan drug designations and approvals list for immunotherapy drugs
Exhibit 06: EU orphan drug designations and approvals list for immunotherapy drugs
Exhibit 07: Phase III pipeline molecules for mAbs
Exhibit 08: Phase II pipeline molecules for mAbs
Exhibit 09: Phase I pipeline molecules for mAbs
Exhibit 10: Pipeline molecules for immune checkpoint inhibitors
Exhibit 11: Phase III pipeline molecules for vaccines
Exhibit 12: Phase II pipeline molecules for vaccines
Exhibit 13: Phase I pipeline molecules for vaccines
Exhibit 14: Near-launch immuno-oncology pipeline assets
Exhibit 15: Global immunotherapy drugs market 2015-2020 ($ billions)
Exhibit 16: Factors influencing global immunotherapy drugs market
Exhibit 17: Challenges faced by US immunologists while prescribing immunotherapy drugs 2015
Exhibit 18: SWOT analysis of global immunotherapy drugs market
Exhibit 19: Five forces analysis
Exhibit 20: Market segmentation by type of immunotherapy drug
Exhibit 21: Timeline of mAbs approval for cancer by US FDA
Exhibit 22: Timeline of mAbs approval for autoimmune, respiratory, and ophthalmic diseases by US FDA
Exhibit 23: Global mAbs market 2015-2020 ($ billions)
Exhibit 24: Key drivers and challenges of global monoclonal antibodies drugs market
Exhibit 25: Top vendor offerings in global mAbs market
Exhibit 26: Global immune checkpoint inhibitors market 2015-2020 ($ billions)
Exhibit 27: Key driver and challenge for global immune checkpoint inhibitors market
Exhibit 28: Top vendor offerings in global immune checkpoint inhibitors market
Exhibit 29: Global vaccines market 2015-2020 ($ billions)
Exhibit 30: Segmentation of global vaccines market by application 2015
Exhibit 31: Key drivers and challenges of global vaccines market
Exhibit 32: Top vendor offerings in global vaccines market
Exhibit 33: Global non-specific immunotherapies market 2015-2020 ($ billions)
Exhibit 34: Key drivers and challenges of global non-specific immunotherapies market
Exhibit 35: Top vendor offerings in global non-specific immunotherapies market
Exhibit 36: Segmentation of global immunotherapy drugs market by type of immunotherapy 2015
Exhibit 37: Global immunotherapy drugs market; YoY revenue and growth rate based on type of immunotherapy 2015-2020 ($ billions)
Exhibit 38: Global immunotherapy drugs market segmentation by therapy area
Exhibit 39: Segmentation of global immunotherapy drugs market by therapy area 2015
Exhibit 40: Segmentation of global immunotherapy drugs market by geography 2015
Exhibit 41: Global immunotherapy drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 42: Immunotherapy drugs market in Americas 2015-2020 ($ billions)
Exhibit 43: Market share in the Americas by type of immunotherapy 2015
Exhibit 44: Immunotherapy drugs market in EMEA 2015-2020 ($ billions)
Exhibit 45: Market share in Europe by type of immunotherapy 2015
Exhibit 46: Immunotherapy drugs market in APAC 2015-2020 ($ billions)
Exhibit 47: Market share in APAC by type of immunotherapy 2015
Exhibit 48: Global immunotherapy drugs market: YoY revenue and growth based on geography 2015-2020 ($ billions)
Exhibit 49: Global incidence of cancers 2015 and 2020
Exhibit 50: Population aged 60 years and over: World, developed, and developing regions (millions)
Exhibit 51: Patient assistance programs for immunotherapy drugs
Exhibit 52: Some pipeline molecules for immunotherapy drugs
Exhibit 53: Impact of drivers
Exhibit 54: Approvals and patent expiries of top-selling immunotherapy drugs
Exhibit 55: Average annual treatment cost per patient for some immunotherapy drugs 2014 ($ millions)
Exhibit 56: Impact of drivers and challenges
Exhibit 57: Expected combination regimen launches in immune-oncology 2015-2020
Exhibit 58: Market share analysis of top vendors0
Exhibit 59: Competitive assessment of top 10 immunotherapy drugs 2015 ($ billions)1
Exhibit 60: YoY sales comparison of top five immunotherapy drugs 2013-2015 ($ billions)1
Exhibit 61: F. Hoffmann-La Roche: Immunotherapy drugs segmentation by revenue 20152
Exhibit 62: F. Hoffmann-La Roche: Top-selling immunotherapy drugs 20152
Exhibit 63: F. Hoffmann-La Roche: YoY revenue and growth rate of MabThera/Rituxan (oncology and immunology indications) 2013-2015 ($ billions)
Exhibit 64: F. Hoffmann-La Roche: YoY revenue and growth rate of MabThera/Rituxan (immunology indications only) 2013-2015 ($ billions)4
Exhibit 65: F. Hoffmann-La Roche: YoY revenue and growth rate of Actemra/RoActemra 2013-2015 ($ billions)5
Exhibit 66: F. Hoffmann-La Roche: Actemra/RoActemra geographic segmentation by revenue 20155
Exhibit 67: F. Hoffmann-La Roche: MabThera/Rituxan geographic segmentation by revenue 20156
Exhibit 68: F. Hoffmann-La Roche: YoY revenue and growth rate of Avastin 2012-2015 ($ billions)7
Exhibit 69: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin 2012-2015 ($ billions)8
Exhibit 70: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin in US 2013-2015 ($ billions)8
Exhibit 71: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin in EU 2013-2015 ($ billions)8
Exhibit 72: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin in Japan 2013-2015 ($ millions)9
Exhibit 73: F. Hoffmann-La Roche: YoY revenue and growth rate of Perjeta 2012-2015 ($ billions)0
Exhibit 74: F. Hoffmann-La Roche: YOY revenue and growth rate of Kadcyla 2013-2015 ($ billions)1
Exhibit 75: F. Hoffmann-La Roche: Key takeaways3
Exhibit 76: AbbVie: Immunotherapy drugs segmentation by revenue 20154
Exhibit 77: AbbVie: YoY revenue and growth rate of HUMIRA 2013-2015 ($ billions)5
Exhibit 78: AbbVie: YoY revenue and growth rate of HUMIRA in US 2013-2015 ($ billions)5
Exhibit 79: AbbVie: YoY revenue and growth rate of HUMIRA in ROW 2013-2015 ($ billions)5
Exhibit 80: AbbVie: Sales of HUMIRA in major markets 20156
Exhibit 81: AbbVie: Key takeaways7
Exhibit 82: Johnson & Johnson: Key immunotherapy drugs segmentation by revenue 20158
Exhibit 83: Johnson & Johnson: Top-selling immunotherapy drugs 20158
Exhibit 84: Johnson & Johnson: YoY revenue and growth rate of Remicade 2012-2015 ($ billions)9
Exhibit 85: Johnson & Johnson: YoY revenue and growth rate of Stelara 2012-2015 ($ billions)0
Exhibit 86: Johnson & Johnson: YoY revenue and growth rate of Stelara in US 2012-2015 ($ billions)0
Exhibit 87: Johnson & Johnson: YoY revenue and growth rate of Stelara in ROW 2012-2015 ($ millions)0
Exhibit 88: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria 2012-2015 ($ billions)1
Exhibit 89: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria in the US 2012-2015 ($ billions)1
Exhibit 90: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria in ROW 2012-2015 ($ billions)2
Exhibit 91: Johnson & Johnson: Key takeaways3
Exhibit 92: Merck: Business segmentation by revenue 20154
Exhibit 93: Merck: Immunotherapy drugs segmentation by revenue 20155
Exhibit 94: Merck: Top-selling immunotherapy drugs 20156
Exhibit 95: Merck: YoY revenue and growth rate of Gardasil/Gardasil9 2012-2015 ($ billions)7
Exhibit 96: Merck: YoY revenue and growth rate of ProQuad/M-M-R II/Varivax 2012-2015 ($ billions)8
Exhibit 97: Merck: YoY revenue and growth rate of Zostavax 2012-2015 ($ millions)8
Exhibit 98: Merck: YoY revenue and growth rate of Pneumovax 23 2012-2015 ($ millions)9
Exhibit 99: Merck: YoY revenue and growth rate of RotaTeq 2012-2015 ($ millions)9
Exhibit 100: Merck: Key takeaways2
Exhibit 101: Amgen: Top-selling immunotherapy drugs 20153
Exhibit 102: Amgen: YoY revenue and growth rate of Enbrel in US and Canada 2012-2015 ($ billions)4
Exhibit 103: Amgen: YoY revenue and growth rate of Enbrel in US 2012-2015 ($ billions)4
Exhibit 104: Amgen: YoY revenue and growth rate of Enbrel in Canada 2012-2015 ($ millions)4
Exhibit 105: Amgen: YoY revenue and growth rate generated from net product sales of Xgeva 2012-2015 ($ billions)5
Exhibit 106: Amgen: YoY revenue and growth rate generated from net product sales of Prolia 2012-2015 ($ billions)5
Exhibit 107: Amgen: YoY revenue and growth rate of Vectibix in US 2012-2015 ($ millions)6
Exhibit 108: Amgen: YoY revenue and growth rate of Vectibix in ROW 2012-2015 ($ millions)6
Exhibit 109: Amgen: Key takeaways9
Exhibit 110: BMS: Business segmentation by revenue 20150
Exhibit 111: BMS: Immunotherapy drugs segmentation by revenue 20150
Exhibit 112: BMS: Top-selling immunotherapy drugs 20151
Exhibit 113: BMS: YoY revenue and growth rate of Orencia 2012-2015 ($ billions)2
Exhibit 114: BMS: YoY revenue and growth rate generated from net product sales of Yervoy 2012-2015 ($ billions)2
Exhibit 115: BMS: YoY revenue and growth rate of Erbitux in US, Canada, and Japan 2012-2015 ($ millions)3
Exhibit 116: BMS: Key takeaways


【レポート販売概要】

■ タイトル:免疫治療薬の世界市場:モノクローナル抗体、免疫チェックポイント阻害薬、ワクチン、非特異的免疫療法
■ 英文:Global Immunotherapy Drugs 2016-2020
■ 発行日:2016年3月29日
■ 調査会社:Technavio
■ 商品コード:IRTNTR8772
■ 調査対象地域:世界
  • 手術用顕微鏡の世界市場
    Developing markets such as the Middle East, Brazil, Argentina, Mexico, China, and India are lucrative markets for surgical microscopes, owing to favorable government incentives. The report segments the surgical microscopes market is segmented on the basis of application, end user, and region. On the basis of applications, the surgical microscopes applications market is categorized into neuro & spi …
  • 2014年戦略提言:イギリスの病院止血診断検査市場
    This new report from Venture Planning Group contains 402 pages, 28 tables, and presents a comprehensive analysis of the UK hospital hemostasis diagnostic testing market, including: Major issues pertaining to the UK coagulation laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years. V …
  • 民間航空機客室内装製品市場の世界市場2014-2018
    About Commercial Aircraft Cabin Interior The interior of an aircraft cabin consists of lights, IFEC, seats, windows, windshield, and others, including the galley and monument, and lavatory. The use of lights, upholstery, color combinations, and other value add-ons add to the overall look of an aircraft's interior. TechNavio's analysts forecast the Global Commercial Aircraft Cabin Interior market t …
  • IT運用分析の世界市場予測(~2022):リアルタイムログ分析、アプリケーション性能管理
    The IT operations analytics (ITOA) market is projected to grow from an estimated USD 2.78 Billion in 2016 to USD 19.84 Billion by 2022, at a CAGR of 38.7% during the forecast period. Major growth drivers for this market include the tremendous growth of IT operations data and adoption of BYOD and IoT in organizations across industries. The solutions provided by various vendors in the ITOA market ar …
  • 通信事業者のビックデータ運用、アプリケーションおよびサービス
    Telcos have a major advantage in that they have many sources of data but if they want to monetize that data and derive meaningful, actionable analytics it could be challenging due to the complexities of correlation, prediction, and the massive volumes of data from different sources. Identifying and leveraging available data sources, especially for external and commercial interests is an important …
  • アルファオレフィン市場(世界市場動向と予測)
    The alpha olefin market is expected to grow at a compound annual growth rate of 4.2% over the next five years and reach 4.6 million metric tons by 2018. North America will continue to dominate the market demand due to bulk of investments and expansion plans of alpha olefins such as 1-hexene and 1-octene in this region. The alpha olefin market is extremely competitive. In terms of the global market …
  • 疎水性コーティング及び表面(疎水性物質)の世界市場2016-2023
    In this report we identify the opportunities that are emerging from the latest developments in hydrophobic materials and surfaces. These include important new materials based on carbon nanotubes, graphene, nanoparticulate calcium carbonate and various nanocomposites, which are slated to create a new breed of “superhydrophobic” products. The report also covers the latest developments from more conv …
  • 2014年戦略提言:ヨーロッパの内分泌機能検査市場
    This new 310-page report from Venture Planning Group provides a comprehensive analysis of the European endocrine function market, including emerging tests, technologies, instrumentation, sales forecasts by country, market shares and strategic profiles of leading suppliers.  The report provides test volume and sales forecasts by country and market segment for the following assays: Cortisol, Es …
  • Imperial Oil Limited:石油・ガスバリューチェーン分析レポート2013
    Imperial Oil Limited Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "Imperial Oil Limited" Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “Imperial Oil Limited”. The report provides key information relating to oil and gas assets of the company along with its operations across the value chain. The report exam …
  • クラウドコンピューティングの世界市場予測(~2023年)
    Increasing need to deliver enhanced customer experience to drive the cloud computing marketThe global cloud computing market size is expected to grow from USD 272.0 billion in 2018 to USD 623.3 billion by 2023, at a Compound Annual Growth Rate (CAGR) of 18.0% during the forecast period. Increased automation and agility, need for delivering enhanced customer experience, and increased cost savings a …
  • 世界のスマートウィンドウ(Smart Window)市場動向(2014-2021)
    NanoMarkets has now been tracking the smart windows for five years and has produced detailed studies of this market and related businesses including the smart windows materials markets and smart auto glass. Our understanding of new high-tech glass markets has been further enhanced by our studies of BIPV glass, self-healing and self-cleaning glass and various segments of the display glass sector. A …
  • HIV/AIDS検査の世界市場2015
    The report presents a detailed analysis of the AIDS diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the definition, epidemiology and etiology of AIDS and other retroviruses are reviewed. The report provides the 5- and 10-year test volume and sales forecasts by country for HIV-1/2, HIV Ag, HTLV-I/II, Western Blot and other confirmator …
  • Hepatic (Liver) Tumor:グローバル臨床試験レビューH2, 2013
    Hepatic (Liver) Tumor Global Clinical Trials Review, H2, 2013 Summary GlobalData's clinical trial report, “Hepatic (Liver) Tumor Global Clinical Trials Review, H2, 2013" provides data on the Hepatic (Liver) Tumor clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hepatic (Liver) Tumor. It includes an overview of the trial numbers and the …
  • STAP(Specialized Threat Analysis and Protection)の世界市場
    About Specialized Threat Analysis and Protection Specialized threat analysis and protection involves detecting and preventing malware-based attacks and cyber-attacks. It includes identity and access management, encryption, intrusion detection, and other advanced security software. They are based on signature-less technology such as sandboxing, emulation, big data analytics, and containerization. T …
  • ブラッシュカッター(刈払機)の世界市場
    About Brush CutterGarden equipment like brush cutters are used to maintain a healthy lawn and garden. Innovations in technology like battery-powered brush cutters and lightweight gardening equipment have encouraged more people to engage in gardening. Competitors are striving to improve the efficiency and functionality of brush cutters and garden equipment to improve customer satisfaction. Technavi …
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。